"Sirolimus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.
| Descriptor ID |
D020123
|
| MeSH Number(s) |
D02.540.505.760
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sirolimus".
Below are MeSH descriptors whose meaning is more specific than "Sirolimus".
This graph shows the total number of publications written about "Sirolimus" by people in this website by year, and whether "Sirolimus" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 4 | 1 | 5 |
| 2005 | 4 | 1 | 5 |
| 2006 | 2 | 1 | 3 |
| 2007 | 4 | 5 | 9 |
| 2008 | 4 | 2 | 6 |
| 2009 | 5 | 3 | 8 |
| 2010 | 0 | 2 | 2 |
| 2011 | 2 | 1 | 3 |
| 2012 | 5 | 3 | 8 |
| 2013 | 8 | 4 | 12 |
| 2014 | 4 | 1 | 5 |
| 2015 | 4 | 0 | 4 |
| 2016 | 2 | 3 | 5 |
| 2017 | 1 | 2 | 3 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 1 | 2 |
| 2020 | 0 | 1 | 1 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sirolimus" by people in Profiles.
-
Medical Treatment of Vascular Anomalies. Dermatol Clin. 2022 Oct; 40(4):461-471.
-
Autophagy modulating therapeutics inhibit ovarian cancer colony generation by polyploid giant cancer cells (PGCCs). BMC Cancer. 2022 Apr 14; 22(1):410.
-
Combinatorial therapy of sirolimus and heparin by nanocarrier inhibits restenosis after balloon angioplasty ex vivo. Nanomedicine (Lond). 2020 05; 15(12):1205-1220.
-
Targeting mTOR in Head and Neck Cancer-Response. Clin Cancer Res. 2019 11 01; 25(21):6555.
-
Platelet Activation by Antiphospholipid Antibodies Depends on Epitope Specificity and is Prevented by mTOR Inhibitors. Thromb Haemost. 2019 Jul; 119(7):1147-1153.
-
Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial. Clin Cancer Res. 2019 02 15; 25(4):1156-1164.
-
Autophagy protects auditory hair cells against neomycin-induced damage. Autophagy. 2017; 13(11):1884-1904.
-
Autoimmune enteropathy and hepatitis in pediatric heart transplant recipient. Pediatr Transplant. 2017 Mar; 21(2).
-
Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial. Transplantation. 2017 Jan; 101(1):157-165.
-
Evidence-Based Management of Vascular Malformations. Facial Plast Surg. 2016 Apr; 32(2):162-76.